In the exemestane-alone group, one death from pneumonia was reported during treatment. The most common grade 3 or 4 4 adverse events were stomatitis , anemia , dyspnea , hyperglycemia , exhaustion , and pneumonitis . Efficacy The trial met its primary end point, progression-free survival; the median progression-free survival, based on radiographic studies assessed by the neighborhood investigators, was 6.9 months for exemestane plus everolimus versus 2.8 months for placebo plus exemestane . The median progression-free of charge survivals based on central assessment were 10.6 months and 4.1 months, respectively .Leonard, M.D., senior vice president, Global Pharmaceutical Research and Development, Abbott. An interview with Dr ChhatwalWhile significant improvement has been made in HCV treatment, there are limitations in efficacy and security for the current standard of care. An extended duration of treatment still outcomes in a less-than 50 percent cure rate in people that have HCV genotype 1. Additionally, the side-effects from interferon therapy can be highly problematic, often including unhappiness and flu-like symptoms.